Oculis launches PIONEER registrational trials for Privosegtor in optic neuritis

Bitget2026/10/01 06:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oculis launched the PIONEER clinical program with two registrational optic neuritis trials following positive Phase 2 ACUITY results.
ACUITY results were already presented, showing neuroprotective benefit with better visual recovery signals in optic neuritis patients.
Privosegtor is also being advanced toward an IND filing in Q4 for acute multiple sclerosis relapses, supported by FDA pre-IND feedback.
The strategy targets an unmet need in MS relapses, where current steroid use shortens episodes but does not prevent lasting disability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oculis launches PIONEER registrational trials for Privosegtor in optic neuritis

You may also like

Crypto prices